Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Tyrosine Kinase Inhibitors Market Heading Into 2029?

In recent years, the market for tyrosine kinase inhibitors has seen robust expansion. The market, which sits at $58.03 billion in 2024, is forecasted to climb to $62.66 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.0%. This growth trajectory seen over the historical period is owed largely to the identification of tyrosine kinases, comprehension of cancer-related signaling pathways, approval of imatinib (Gleevec), early clinical success with TKIs, and significant investment in research and development.

The market size for tyrosine kinase inhibitors is projected to experience significant expansion in the upcoming years. Its projected growth rate will reach “$87.14 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This expected surge during the forecast period is primarily due to the increased investments in healthcare, therapies based on biomarkers, advancements in drug delivery, the model of precision medicine, and an emphasis on pediatric oncology. The major market trends during this period are expected to be strategies to overcome resistance, development of tkis that can penetrate the central nervous system, applications beyond oncology, use of liquid biopsies for monitoring, and considerations of health economics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp

Which Factors Are Pushing The Tyrosine Kinase Inhibitors Market Forward?

The escalating rates of cancer are anticipated to stimulate the expansion of the tyrosine kinase inhibitors market in the forthcoming period. Cancer embodies a wide spectrum of diseases commencing in any organ or tissue within the body where irregular cells uncontrollably multiply, trespass their typical boundaries to infiltrate the adjacent body parts and disseminate to other organs. Tyrosine kinase inhibitors are employed in targeted therapy to aim and eradicate specific cancer cell varieties by obstructing tyrosine kinases that help in curtailing the proliferation of cancer cells. For example, in January 2023, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported an increase in the number of cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, an augmentation of 3.16%. Consequently, the rising prevalence of cancer is fuelling the growth of the tyrosine kinase inhibitors market.

The tyrosine kinase inhibitors market covered in this report is segmented –

1) By Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types

2) By Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies

3) By Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications

Subsegments:

1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib

2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib

3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Pazopanib, Axitinib, Regorafenib

4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors, RET Tyrosine Kinase Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Other Emerging Tyrosine Kinase Inhibitors

What Long-Term Trends Are Likely To Affect The Tyrosine Kinase Inhibitors Market?

A prevailing trend increasing in popularity in the tyrosine kinase inhibitor market is that of product innovations. To remain relevant in this market, leading companies are embracing novel technologies. For instance, Xspray Pharma AB, a pharmaceutical firm based in Sweden, partnered with EVERSANA, an American life sciences service company, in February 2023. This collaboration was established to support the U.S. debut and commercialization of their pioneering cancer treatment, Dasynoc, which is designed to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc provides a fresh and unique treatment approach for CML and ALL patients in the U.S. market for Tyrosine Kinase Inhibitors, a market worth $3.5 billion. This represents a substantial development for CML patients – as per the retrospective registry data shared at ASH 2022, the 5-year overall survival rate was found to be almost 79% for those treated with a combination of a tyrosine kinase inhibitor (TKI) and a proton pump inhibitor (PPI), such as omeprazole. This is compared to a survival rate of 94% for patients treated with TKI alone.

Which Organizations Are Driving Progress In The Tyrosine Kinase Inhibitors Industry?

Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Tyrosine Kinase Inhibitors Industry?

North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11957&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model